(-0.34%) 5 018.39 points
(0.23%) 37 903 points
(-0.33%) 15 605 points
(0.29%) $79.23
(0.93%) $1.950
(0.97%) $2 333.50
(1.04%) $27.03
(1.37%) $968.00
(0.03%) $0.933
(0.02%) $11.03
(-0.04%) $0.798
(0.06%) $93.51
0.00% HKD 5.40
Live Chart Being Loaded With Signals
Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China...
Stats | |
---|---|
Volumen de hoy | 3.42M |
Volumen promedio | 5.13M |
Capitalización de mercado | 14.09B |
EPS | HKD0 ( 2024-03-28 ) |
Próxima fecha de ganancias | ( HKD0 ) 2024-06-14 |
Last Dividend | HKD0.176 ( 2023-06-19 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 18.62 |
ATR14 | HKD0.00900 (0.17%) |
Volumen Correlación
Simcere Pharmaceutical Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Simcere Pharmaceutical Correlación - Moneda/Commodity
Simcere Pharmaceutical Finanzas
Annual | 2023 |
Ingresos: | HKD6.61B |
Beneficio Bruto: | HKD4.98B (75.43 %) |
EPS: | HKD0.270 |
FY | 2023 |
Ingresos: | HKD6.61B |
Beneficio Bruto: | HKD4.98B (75.43 %) |
EPS: | HKD0.270 |
FY | 2023 |
Ingresos: | HKD0 |
Beneficio Bruto: | HKD0 (0.00 %) |
EPS: | HKD0 |
FY | 2022 |
Ingresos: | HKD6.32B |
Beneficio Bruto: | HKD5.00B (79.08 %) |
EPS: | HKD0.400 |
Financial Reports:
No articles found.
Simcere Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.176 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.180 | 2021-06-29 |
Last Dividend | HKD0.176 | 2023-06-19 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | HKD0.532 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.23 | -- |
Div. Sustainability Score | 8.58 | |
Div.Growth Potential Score | 2.73 | |
Div. Directional Score | 5.65 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
6083.HK | Ex Dividend Knight | 2023-06-12 | Semi-Annually | 0 | 0.00% | |
1843.HK | Ex Dividend Knight | 2023-09-05 | Annually | 0 | 0.00% | |
0868.HK | Ex Dividend Knight | 2023-08-11 | Semi-Annually | 0 | 0.00% | |
0016.HK | Ex Dividend Knight | 2023-11-06 | Semi-Annually | 0 | 0.00% | |
2633.HK | Ex Dividend Knight | 2023-08-15 | Semi-Annually | 0 | 0.00% | |
1412.HK | Ex Dividend Knight | 2023-06-12 | Semi-Annually | 0 | 0.00% | |
0497.HK | Ex Dividend Junior | 2023-08-25 | Annually | 0 | 0.00% | |
6858.HK | Ex Dividend Knight | 2023-09-20 | Semi-Annually | 0 | 0.00% | |
1962.HK | Ex Dividend Junior | 2023-09-11 | Annually | 0 | 0.00% | |
0992.HK | Ex Dividend Knight | 2023-07-26 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.108 | 1.500 | 7.84 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0659 | 1.200 | 7.80 | 9.37 | [0 - 0.3] |
returnOnEquityTTM | 0.0878 | 1.500 | -0.135 | -0.203 | [0.1 - 1] |
payoutRatioTTM | 0.587 | -1.000 | 4.13 | -4.13 | [0 - 1] |
currentRatioTTM | 2.10 | 0.800 | 4.50 | 3.60 | [1 - 3] |
quickRatioTTM | 1.736 | 0.800 | 4.49 | 3.59 | [0.8 - 2.5] |
cashRatioTTM | 0.747 | 1.500 | 6.96 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.132 | -1.500 | 7.81 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.0581 | 2.00 | 9.98 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -0.128 | 2.00 | -0.0639 | -0.128 | [0 - 20] |
debtEquityRatioTTM | 0.198 | -1.500 | 9.21 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.754 | 1.000 | 0.762 | 0.762 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.108 | 1.000 | 9.85 | 9.85 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.106 | 1.000 | -0.524 | -0.524 | [0.2 - 2] |
assetTurnoverTTM | 0.609 | 0.800 | 9.27 | 7.42 | [0.5 - 2] |
Total Score | 8.58 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 17.79 | 1.000 | 8.30 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0878 | 2.50 | -0.0869 | -0.203 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.128 | 2.00 | -0.0426 | -0.128 | [0 - 30] |
dividendYielPercentageTTM | 3.59 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.0581 | 2.00 | 9.98 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.587 | 1.500 | 4.13 | -4.13 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0229 | 1.000 | -1.929 | 0 | [0.1 - 0.5] |
Total Score | 2.73 |
Simcere Pharmaceutical
Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. It focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. The company's principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Softan, a rosuvastatin calcium tablet; ZAILIN, an amoxicillin granules/dispersible tablet/capsule; Iremod, an iguratimod tablet; Antine, a diclofenac sodium sustained release capsule/gel; and Orencia, an abatacept injection. It also offers promotion services for pharmaceutical products. Simcere Pharmaceutical Group Limited has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize medicines targeting the neurotoxicity amyloid protein N3pE (pGlu-Aß) to treat Alzheimer's disease. The company was founded in 1995 and is headquartered in Nanjing, China.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico